Clinical trial · Interventional
A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma
A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma
NCT07589257CI-TRIAL-00111754recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Intrinsic Pontine Glioma | Diffuse Intrinsic Pontine Glioma | ONTOLOGY_EXACT | 0.98 |
| Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Midline Glioma, H3 K27M-Mutant | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VRT106 for injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VRT106
- description
- VRT106
- interventionNames
- Drug: VRT106 for injection
Primary outcomes (1)
- measure
- Disease Control Rate
- timeFrame
- About 2 years
- description
- Evaluations will be performed at 6 weeks (± 3 days) following the completion of radiotherapy, subsequently every 9 weeks (± 7 days) during the first year of treatment, and then every 12 weeks (± 7 days) thereafter.
Secondary outcomes (2)
- measure
- Progression-Free Survival
- timeFrame
- About 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures. * Male or female adults aged 18 to 75 years at the time of signing the ICF. * Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \>50% of the pons volume, with diffuse brainstem enlargement. * Karnofsky Performance Status (KPS) score ≥ 60. * Expected survival time ≥ 3 months. Exclusion Criteria: * Individuals with extracranial metastases. * Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination. * Active hemorrhage detected on cranial MRI scan prior to enrollment. * Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants). * Prior receipt of oncolytic virus therapy or other gene therapy agents.
References
Publications (0)
Data not yet available
No reference posted for this study.